Trial Profile
Study of the human anti-TNF-antibody [anti-tumour necrosis factor-antibody] adalimumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 22 Apr 2008 New trial record.